[Helicobacter pylori eradication. Therapeutic evolution, value of complementary studies]

Area of Science:

• Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Helicobacter pylori (H. pylori) infection is a significant cause of gastroduodenal ulcers and MALT lymphoma.
• Eradication of H. pylori alters disease progression and reduces recurrence risk for specific conditions.

Purpose of the Study:

• To outline indications, diagnostic methods, and therapeutic regimens for H. pylori eradication.
• To provide guidance on follow-up and treatment efficacy assessment.

Main Methods:

• Diagnosis is confirmed via direct tests (urease, pathology) and efficacy assessed by indirect tests (13C-urea breath test).
• A 7-day tri-therapy regimen includes a proton pump inhibitor, amoxicillin, and clarithromycin.
• Metronidazole is an alternative for penicillin-allergic patients; retreatment may involve substituting clarithromycin.

Main Results:

• The standard tri-therapy regimen achieves a mean eradication rate of 67% in France.
• Key factors influencing treatment failure include poor patient compliance and bacterial resistance to clarithromycin.
• Treatment efficacy can be monitored via breath tests or gastric biopsies.

Conclusions:

• H. pylori eradication is indicated for gastroduodenal ulcers and low-grade MALT lymphoma.
• Systematic eradication is not advised for H. pylori-associated dyspepsia or gastric adenocarcinoma prevention.
• Follow-up assessment of eradication efficacy is recommended, particularly for duodenal ulcers.